- Home
- MGLD vs ELTX Comparison
MGLD vs ELTX Comparison
Compare MGLD & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- ELTX
- Stock Information
- Founded
- MGLD 1996
- ELTX 2011
- Country
- MGLD United States
- ELTX United States
- Employees
- MGLD N/A
- ELTX N/A
- Industry
- MGLD Finance/Investors Services
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- ELTX Health Care
- Exchange
- MGLD Nasdaq
- ELTX Nasdaq
- Market Cap
- MGLD 59.9M
- ELTX 54.6M
- IPO Year
- MGLD N/A
- ELTX 2021
- Fundamental
- Price
- MGLD $1.50
- ELTX $5.05
- Analyst Decision
- MGLD
- ELTX Strong Buy
- Analyst Count
- MGLD 0
- ELTX 3
- Target Price
- MGLD N/A
- ELTX $9.50
- AVG Volume (30 Days)
- MGLD 11.1K
- ELTX 27.5K
- Earning Date
- MGLD 02-12-2025
- ELTX 11-13-2024
- Dividend Yield
- MGLD N/A
- ELTX N/A
- EPS Growth
- MGLD N/A
- ELTX N/A
- EPS
- MGLD N/A
- ELTX N/A
- Revenue
- MGLD $32,511,000.00
- ELTX N/A
- Revenue This Year
- MGLD N/A
- ELTX N/A
- Revenue Next Year
- MGLD N/A
- ELTX N/A
- P/E Ratio
- MGLD N/A
- ELTX N/A
- Revenue Growth
- MGLD N/A
- ELTX N/A
- 52 Week Low
- MGLD $0.78
- ELTX $2.96
- 52 Week High
- MGLD $1.92
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- MGLD 54.48
- ELTX 49.92
- Support Level
- MGLD $1.32
- ELTX $4.72
- Resistance Level
- MGLD $1.58
- ELTX $5.45
- Average True Range (ATR)
- MGLD 0.13
- ELTX 0.37
- MACD
- MGLD 0.01
- ELTX -0.02
- Stochastic Oscillator
- MGLD 75.42
- ELTX 33.61
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.